The purpose of this article is to assess the feasibility of an office-based renal mass biopsy (RMB), which might constitute a paradigm change in clinical practise. Despite quicker detection of patients with renal tumours, the absence of evidence of a reduction in cancer-specific mortality calls for a review of treatment procedures. When compared to biopsy practise for all other neoplasms in every other solid organ (save the testis), RMB is underused, and the bulk of RMB done is outsourced to interventional radiologists. An ultrasound-guided, office-based RMB is safe, repeatable, and has a significant influence on management decisions.
Percutaneous RMB is increasingly being used in clinical practise, and it has a significant influence on treatment options for renal tumours. It is possible to incorporate ultrasound-guided biopsy of a renal tumour into clinical practise, and in modern practise, the urologist has the skill set to execute the procedure consistently, with low morbidity, and with minimum patient pain.
Reference: https://link.springer.com/article/10.1007/s11934-021-01059-5
